-
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) have formed a new strategic collaboration to advance multiple gene therapies for neurological disorders.
-
Voyager has a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding and 50/50 cost Receive $175 million in upfront consideration, including the option to select – US profit sharing of GBA1 program following Phase 1 readout.
-
The collaboration includes Voyager’s preclinical GBA1 gene therapy program for Parkinson’s disease and other GBA1-mediated diseases. It combines the GBA1 gene replacement payload with a novel capsid from Voyager’s TRACER platform.
-
Additionally, Neurocrine Biosciences and Voyager have also agreed to collaborate on three novel gene therapy programs directed at rare CNS targets, each utilizing Voyager’s new TRACER capsids.
-
For its GBA1 gene therapy program, Neurocrine Biosciences has agreed to fund its development through the completion of its first Phase 1 trial.
-
Following data readout, Voyager has the right to choose to co-develop and co-commercialize the GBA1 program with Neurocrine Biosciences of the United States under a 50/50 cost and profit sharing arrangement. , is not obligatory.
-
If Voyager declines the cost and profit sharing option in the GBA1 program, it will be eligible to receive development milestone payments of up to $985 million, plus significant potential commercial milestone payments and tiered royalties there is.
-
Price action: VYGR shares rose 28.16% to $8.92 during Monday’s final check premarket session.
See other products from Benzinga
Don’t miss real-time stock alerts – join Benzinga Pro for free! Explore tools that help you make smarter, faster and better investments.
© 2023 Benzinga.com. Benzinga does not provide investment advice. all rights reserved.
